<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161526">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02012595</url>
  </required_header>
  <id_info>
    <org_study_id>2013-01</org_study_id>
    <secondary_id>2013-003775-35</secondary_id>
    <nct_id>NCT02012595</nct_id>
  </id_info>
  <brief_title>[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease</brief_title>
  <official_title>[11C]DONEPEZIL PET FOR IMAGING THE AUTONOMOUS NERVOUS SYSTEM IN PARKINSONS DISEASE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Borghammer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lundbeck Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jascha Fonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonden af 2. Juli 1984 til bekæmpelse af Parkinsons Sygdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIM: Investigate wether there are differences in the parasympathetic nervous system in
      Parkinsons patients compared to controls.

      MATERIALS AND METHODS: We use the tracer [11C]donepezil to image the parasympathetic nervous
      system. The Investigators will include 20 Parkinsons patients and 20 healthy controls aged
      40-80 in our study. The participants will receive a careful medical examination, including a
      neurological examination, as part of the inclusion process. The subjects also have an MRI
      scan of the brain. Then PET/CT scans with [11C]donepezil are conducted - once for the upper
      abdominal region and once for the head region. For evaluating the function of the
      parasympathetic nervous system gastric emptying time, heart rate variability and salivary
      flow will be measured. These measureless will be correlated to the PET findings.

      PERSPECTIVES: The study will potentially result in the development of a PET ligand for
      imaging the parasympathetic nervous system. This will have applications for research in
      Parkinson's disease, diabetes, heart disease and other disorders, in which the autonomic
      nervous system is involved
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Distribution volume of [11C]donepezil in internal organs</measure>
    <time_frame>The distribution volume of [11C]donepezil is measured at &quot;Day 1&quot; by PET/CT scanning each participant. The data analysis is done when all participants have completed the study.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Our primary endpoint is the distribution volume of [11C]donepezil in internal organs (including salivary glands, heart, stomach and intestines) in Parkinson's patients compared to controls.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's patients</arm_group_label>
    <description>Participants with Parkinson's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[11C]donepezil PET</intervention_name>
    <arm_group_label>Parkinson's patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson's patients with moderate symptoms (diagnosis &gt; 4 years earlier, bilateral
        disease). Will be recruited through department of neurology Aarhus University Hospital,
        Denmark.

        Healthy controls recruited through local media.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40-80 years

        Exclusion Criteria:

          -  dementia,

          -  psychiatric diseases,

          -  serious medical illness including any type of previous cancer

          -  any drug with known interaction with the autonomic nervous system

          -  metal in the body (because of MR scan)

          -  pregnancy or breast feeding (because of radiation due to PET/CT)

          -  known diseases of the salivary glands, stomach, intestines.

          -  Prior major surgery to salivary glands, esophagus, stomach.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Borghammer, MD, PhD,DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Nuclear Medicine &amp; PET Center, Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trine Gjerløff, MD</last_name>
    <email>trine@cfin.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Nuclear Medicine &amp; PET Center, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Trine Gjerløff, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per Borghammer, MD, PhD,DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Per Borghammer</investigator_full_name>
    <investigator_title>MD, ph.d.,DMSci</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
